Apratastat

DB13020InvestigationalSmall molecule

Tmi 005 is under investigation in clinical trial NCT00095342 (Study Evaluating TMI-005 in Active Rheumatoid Arthritis).

Mechanism: Pharmacologically active on Disintegrin and metalloproteinase domain-containing protein 17 and Collagenase 3
Curator reviewed
Formula / weight: C₁₇H₂₂N₂O₆S₂ · 414.49 g/mol (avg)
Code names: TMI-005

Resolves to

Compound

Structure

InChIKeyMAVDNGWEBZTACC-HNNXBMFYSA-NSMILESCC1(C)SCCN([C@H]1C(=O)NO)S(=O)(=O)C1=CC=C(OCC#CCO)C=C1

Targets

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Apratastat, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.